Drug Overview

The gp100:280-288(288V) peptide vaccine is an investigational cancer vaccine designed to treat patients with advanced melanoma. It belongs to a class of immunotherapies known as peptide-based vaccines, which aim to “train” the patient’s own immune system to recognize and attack cancer cells.

This specific vaccine targets a fragment of the gp100 antigen, a protein found in high concentrations on the surface of melanoma cells. By modifying the natural peptide sequence, scientists have created a “synthetic” version that is significantly more effective at triggering an immune response than the protein produced by the tumor itself.

Generic Name: gp100:280-288(288V) peptide vaccine.
Target: gp100 antigen (glycoprotein 100).
HLA Type: HLA-A*0201 positive.
Drug Class: Cancer Vaccine / Peptide Immunotherapy.
Route of Administration: Subcutaneous or Intradermal injection.
FDA Approval Status: Investigational. As of March 2026, it is not FDA-approved for general use but remains a key component of clinical trials, particularly in combination with other immunotherapies like IL-2 or checkpoint inhibitors.

What Is It and How Does It Work? (Mechanism of Action)

The gp100:280-288(288V) vaccine works through a process called T-cell redirection and activation.

The “288V” Modification

Naturally occurring gp100 peptides on tumor cells often have a “weak” binding affinity to the immune system’s receptors. This allows the cancer to go unnoticed. In this vaccine, the amino acid at position 288 has been changed to Valine (V). This single modification allows the peptide to lock much more securely into the HLA-A*0201 molecule on the surface of antigen-presenting cells (APCs).

Molecular Level Mechanisms

Antigen Presentation: Once injected, the synthetic peptide is picked up by APCs (like dendritic cells). Because of the 288V modification, the APCs display the “danger signal” more prominently.
T-cell Priming: Cytotoxic T-lymphocytes (Killer T-cells) “bump” into these APCs. The T-cells recognize the gp100 fragment and become “primed” or activated.
Expansion: These activated T-cells multiply into an army of millions, all specifically programmed to search for any cell in the body displaying the gp100 protein.
Targeted Destruction: The T-cells travel through the bloodstream to the tumor site, bind to the melanoma cells, and release toxic granules (perforins and granzymes) to destroy the cancer.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for this vaccine.

It is strictly available through participation in clinical trials (such as NCT00003061 or NCT00019695). It is primarily studied for:

Metastatic Melanoma: For patients with Stage III or Stage IV disease.
Uveal Melanoma: A rare form of melanoma affecting the eye.
Adjuvant Therapy: Investigated in patients who have had surgery but are at high risk of the cancer returning.

Dosage and Administration Protocols

Because this is an investigational drug, the dosage varies by trial. However, the standard research protocol typically involves the following:

Treatment Detail	Research Specification
Route	Subcutaneous (under the skin) or Intradermal (in the skin).
Adjuvant	Often mixed with Montanide ISA-51 (an oil-based liquid) to keep the vaccine at the injection site longer, increasing immune exposure.
Schedule	Typically administered once every 3 weeks for 4 to 12 cycles.
Combination	Frequently administered alongside high-dose Interleukin-2 (IL-2) to boost the growth of the newly trained T-cells.

Clinical Efficacy and Research Results

The development of the gp100:280-288(288V) vaccine provided one of the first proofs that vaccines could shrink tumors in humans.

The Schwartzentruber Study: A landmark Phase III trial published in the New England Journal of Medicine showed that adding the gp100 vaccine to IL-2 therapy significantly increased the objective response rate (tumor shrinkage) and improved progression-free survival compared to using IL-2 alone.
Immune Memory: Unlike chemotherapy, which stops working once the drug leaves the body, this vaccine can create “memory T-cells” that stay in the body for years, potentially providing long-term protection against relapse.
HLAs Requirement: A major limitation is that the vaccine only works in patients who are HLA-A*0201 positive (a genetic marker found in about 40-50% of Caucasians).

Safety Profile and Side Effects

The vaccine is generally well-tolerated, with most side effects being “on-target” immune responses.

Common Side Effects:

Injection Site Reactions: Redness, swelling, and a hard lump (granuloma) where the shot was given. This is a sign the immune system is responding.
Flu-like Symptoms: Fever, chills, and muscle aches (especially if given with IL-2).
Fatigue: A general sense of tiredness.

Serious Risks (Usually associated with IL-2 combination):

Capillary Leak Syndrome: A condition where fluid leaks from small blood vessels, leading to low blood pressure and swelling.
Autoimmune Vitiligo: The immune system may attack normal pigment cells in the skin, leading to white patches. In melanoma research, vitiligo is often considered a “good sign” that the vaccine is working.

Research Areas

In Stem Cell and Regenerative Medicine, this vaccine is being used to study “T-cell Reconstitution.” Researchers are looking at how to use the gp100 vaccine to “re-educate” the immune system after a bone marrow or stem cell transplant. By giving the vaccine to a patient after they receive new stem cells, doctors hope to ensure that the new immune system is specifically “programmed” to prevent the melanoma from ever coming back.

Patient Management and Practical Recommendations

Pre-treatment Tests:

HLA Typing: This is mandatory. You must have a blood test to confirm you are HLA-A*0201 positive, or the vaccine will not be effective.
Imaging (CT/PET): To establish a baseline of tumor size.

Precautions:

Steroid Avoidance: Patients are generally told to avoid high-dose steroids (like prednisone) while getting the vaccine, as steroids can “turn off” the immune response the vaccine is trying to build.
Monitoring: If given with IL-2, patients usually require monitoring in a specialized hospital unit.

“Do’s and Don’ts”:

DO expect a small, painless lump at the injection site that may last for weeks.
DO report any new white patches on your skin (vitiligo) to your doctor.
DON’T ignore a high fever or “shaking chills.”
DON’T skip scheduled doses, as the “booster” effect is necessary for the immune army to reach full strength.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. The gp100:280-288(288V) vaccine is an investigational agent and is not currently approved by the FDA for general use. Always consult with a qualified oncologist regarding your diagnosis and eligibility for clinical trials.